• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.

作者信息

Legros Laurence, Rousselot Philippe, Giraudier Stéphane, Tulliez Michel, Huguet Françoise, Nicolini Franck-Emmanuel, Mahon Francois-Xavier

出版信息

Blood. 2012 Aug 30;120(9):1959-60. doi: 10.1182/blood-2012-02-408229.

DOI:10.1182/blood-2012-02-408229
PMID:22936742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3433098/
Abstract
摘要

相似文献

1
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.对具有第二次持续完全分子反应的慢性期慢性髓性白血病患者停用伊马替尼的第二次尝试。
Blood. 2012 Aug 30;120(9):1959-60. doi: 10.1182/blood-2012-02-408229.
2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
3
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.在停止伊马替尼治疗后疾病持续不可检测的慢性期慢性髓性白血病患者中，主要分子学反应缺失可作为重新开始酪氨酸激酶抑制剂治疗的触发因素。
J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.
4
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.探索靶向BCR-ABL1的药物对慢性髓性白血病的治疗潜力。
Lancet Oncol. 2010 Nov;11(11):1010-1. doi: 10.1016/S1470-2045(10)70243-6. Epub 2010 Oct 19.
5
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.慢性粒细胞白血病中停用伊马替尼：请勿在家自行尝试。
Leuk Lymphoma. 2009 Jun;50(6):868-70. doi: 10.1080/10428190902934951.
6
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.由BCR-ABL调节的凋亡微小RNA表达与慢性粒细胞白血病进展及伊马替尼耐药相关。
Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11.
7
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.BCL2L11（BIM）缺失多态性可能是慢性髓性白血病患者停用伊马替尼的一个标准。
Br J Haematol. 2013 Jan;160(2):269-71. doi: 10.1111/bjh.12111. Epub 2012 Nov 1.
8
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.波兰慢性髓性白血病患者接受伊马替尼治疗时BCR-ABL基因突变的频率：MAPTEST研究的最终报告
Pol Arch Med Wewn. 2009 Dec;119(12):789-94.
9
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.对于在伊马替尼治疗下达到完全细胞遗传学缓解的慢性髓性白血病患者，其分子学反应的取得取决于是否有较好的依从性。
J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.
10
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.来自印度的慢性髓性白血病患者中对伊马替尼疑似耐药的BCR-ABL激酶结构域突变谱——突变罕见且分布各异。
Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.

引用本文的文献

1
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.达沙替尼再治疗后慢性髓性白血病患者第二次 TKI 停药尝试的无治疗缓解：DAstop2 试验的中期结果。
Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. Epub 2024 Jan 26.
2
Exploration of treatment-free remission in CML, based on molecular monitoring.基于分子监测的 CML 无治疗缓解探索。
Cancer Med. 2024 Jan;13(1):e6849. doi: 10.1002/cam4.6849. Epub 2023 Dec 22.
3
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.酪氨酸激酶抑制剂在慢性髓性白血病中的停药：适应证标准和成功预测因素。
Am J Hematol. 2022 Aug;97(8):1075-1085. doi: 10.1002/ajh.26556. Epub 2022 Apr 12.
4
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.慢性髓性白血病的无治疗缓解：患者视角和未满足需求领域。
Leukemia. 2020 Aug;34(8):2102-2112. doi: 10.1038/s41375-020-0867-0. Epub 2020 May 26.
5
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.使用第一代和第二代酪氨酸激酶抑制剂实现无治疗缓解。
Am J Hematol. 2019 Mar;94(3):346-357. doi: 10.1002/ajh.25342. Epub 2018 Nov 25.
6
Treatment-free remission in patients with chronic myeloid leukemia.慢性髓性白血病患者的无治疗缓解
Int J Hematol. 2018 Oct;108(4):355-364. doi: 10.1007/s12185-017-2295-0. Epub 2017 Jul 8.
7
Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia.流式细胞术检测慢性髓性白血病中 BCR-ABL1 融合蛋白的血细胞。
Sci Rep. 2017 Apr 4;7(1):623. doi: 10.1038/s41598-017-00755-y.
8
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.ABL酪氨酸激酶抑制剂停止用于慢性髓性白血病研究的当前状况。
Stem Cell Investig. 2016 Aug 9;3:36. doi: 10.21037/sci.2016.07.08. eCollection 2016.
9
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.酪氨酸激酶抑制：慢性期慢性髓性白血病治疗管理的一个治疗靶点。
Expert Rev Anticancer Ther. 2013 Dec;13(12):1433-52. doi: 10.1586/14737140.2013.859074.

本文引用的文献

1
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.